Rett

Orphan designation: Adeno-associated viral vector serotype 9 containing the human MECP2 gene, an intron encoding a miRNA generating sequence, and complementary miRNA binding sites Treatment of Rett syndrome, 12/01/2024 Positive

Retrieved on: 
Thursday, April 18, 2024
MECP2, Patient, Committee, EMA, IRIS, Rett, Rett syndrome, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for treatment of the Rett syndrome on 12 January 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Robbins LLP Reminds Investors to Seek Counsel in the Class Action Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
Friday, April 5, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

SHAREHOLDER ALERT: Barrack, Rodos & Bacine Notifies Shareholders of Anavex Life Sciences Securities Class Action Lawsuit

Retrieved on: 
Wednesday, March 27, 2024
Cendant, AIG, Patient, History, News, Rett, MCI Inc., McKesson Corporation, Rett syndrome, Complaint, Myenteric plexus, Fraud, Excellence

PHILADELPHIA, March 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that a class action lawsuit has been filed on behalf of investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased the stock between February 1, 2022 and January 1, 2024 (the “Class Period”).

Key Points: 
  • PHILADELPHIA, March 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that a class action lawsuit has been filed on behalf of investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased the stock between February 1, 2022 and January 1, 2024 (the “Class Period”).
  • If you purchased Anavex stock during the Class Period and sustained a loss on your investment in these shares, you are encouraged to contact us about your rights in this matter and the possibility of leading this class action lawsuit.
  • You may contact the firm about this matter by calling Linda Border or Mark Stein at 877-386-3304, or via email at [email protected] .
  • The complaint alleges Anavex falsely portrayed to investors its research program and the likelihood that its Rett syndrome trials would be successful.

AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Monday, March 25, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

AVXL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corporation Class Action

Retrieved on: 
Thursday, March 21, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.
  • Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 13, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

SHAREHOLDER ALERT: Barrack, Rodos & Bacine Notifies Shareholders of Anavex Life Sciences Securities Class Action Lawsuit

Retrieved on: 
Monday, March 18, 2024
Cendant, AIG, Patient, History, News, Rett, MCI Inc., McKesson Corporation, Rett syndrome, Complaint, Myenteric plexus, Fraud, Excellence

PHILADELPHIA, March 18, 2024 (GLOBE NEWSWIRE) --  The law firm of Barrack, Rodos & Bacine announces that a class action lawsuit has been filed on behalf of investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased the stock between February 1, 2022 and January 1, 2024 (the “Class Period”).

Key Points: 
  • PHILADELPHIA, March 18, 2024 (GLOBE NEWSWIRE) --  The law firm of Barrack, Rodos & Bacine announces that a class action lawsuit has been filed on behalf of investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased the stock between February 1, 2022 and January 1, 2024 (the “Class Period”).
  • If you purchased Anavex stock during the Class Period and sustained a loss on your investment in these shares, you are encouraged to contact us about your rights in this matter and the possibility of leading this class action lawsuit.
  • You may contact the firm about this matter by calling Linda Border or Mark Stein at 877-386-3304, or via email at [email protected] .
  • The complaint alleges Anavex falsely portrayed to investors its research program and the likelihood that its Rett syndrome trials would be successful.

AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Sunday, March 17, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
Thursday, March 14, 2024
Success, Central nervous system, Patient, SAN, CNS, News, LLP, Rett, Rett syndrome, Complaint, Likelihood function, Excellence, Clinical trial, Person, Pharmaceutical industry

SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1, 2024.

Key Points: 
  • SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1, 2024.
  • The Allegations: Robbins LLP is Investigating the Allegations that Anavex Life Sciences Corporation (AVXL) Misled Investors Regarding the Likelihood of Success of its Clinical Trial.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
Thursday, March 14, 2024
Rett, Excellence, District court, Complaint, News, Person

Investors who purchased or otherwise acquired shares of Anavex should contact the Firm prior to the May 13, 2024 lead plaintiff motion deadline.

Key Points: 
  • Investors who purchased or otherwise acquired shares of Anavex should contact the Firm prior to the May 13, 2024 lead plaintiff motion deadline.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Anavex Class Action Lawsuit

Retrieved on: 
Wednesday, March 13, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.